For reference, the Coimbra Protocol (CP) was developed by Dr. Cicero Coimbra, MD, PhD, a neurologist in São Paulo, Brazil. He uses this protocol to treat his patients with MS and other autoimmune disorders and has a 95% MS remission rate. The following link will take you to a world map of CP trained doctors. There are five CP trained doctors here in the US.
https://www.google.com/maps/d/viewer?mid=1fATZJUEhOsYYJdBY41h48FBkLaQ&ll=35.75118934523871%2C-97.08285860000004&z=4
The CP is very similar to the anti-inflammatory regimen treatment protocol for CH and Migraines with the following exceptions. The starting vitamin D3 maintenance dose in the CP is 1000 IU per Kg body weight per day. After that, the vitamin D3 dose is adjusted (up or down) to keep the parathyroid hormone (PTH) serum concentration in the low normal range. For a sleek rascal like me weighing in at 80 Kg, I would be starting the CP at a vitamin D3 maintenance dose of 80,000 IU/day. That’s 8 times the vitamin D3 dose taken by the average CHer following the anti-inflammatory regimen treatment protocol to control and prevent CH.
Patients following thie CP must avoid calcium rich foods like dairy products and drink 2.5 liters of water a day to keep the serum calcium level within its normal reference range.
This article is long and detailed so here’s the bottom line. Taking high-dose vitamin D3 (10,000 IU/day and much higher) is very safe as long as the protocols are followed with lab assays for serum 25(OH)D3, calcium and PTH..
Conclusions
In summary, to our knowledge, our work provides the first long-term documentation of selected critical laboratory parameters during the application of the CP using a high-dose oral vitamin D3 in a broad spectrum of different autoimmune diseases, demonstrating that this procedure is well tolerated with respect to renal function and calcium metabolism. In terms of individualized treatment, we suggest to further use serum levels of PTH as biomarker for an individual response to vitamin D3, the individual ability to convert vitamin D to the active metabolite, the 1,25(OH)2D’s interaction with its receptor and the response elements and finally the differential supplementation with vitamin D3. In further studies, possible differences of the clinical outcome of CP treatment should be investigated.
Take care,
V/R, Batch